⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498177 | 0.60 | — | — | |
| SCHEMBL8677382 | 0.58 | — | — | |
| SCHEMBL16173558 | 0.57 | TSHR (0.70) | — | |
| SCHEMBL6409752 | 0.56 | — | — | |
| SCHEMBL15227132 | 0.55 | — | — | |
| SCHEMBL14991633 | 0.54 | — | — | |
| SCHEMBL6525178 | 0.54 | — | — | |
| SCHEMBL3927441 | 0.51 | — | — | |
| SCHEMBL8398206 | 0.51 | — | — | |
| SCHEMBL1149106 | 0.51 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655243-B2 | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2023-05-23 | — | — | US | claimed |
| EP-3814337-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2021-05-05 | — | — | EP | claimed |
| US-20210115027-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-22 | — | — | US | claimed |
| CN-112074513-A | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists | 豪夫迈·罗氏有限公司 | 2020-12-11 | — | — | CN | claimed |
| WO-2020002270-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-01-02 | — | — | WO | claimed |
| CN-112074513-B | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists | 豪夫迈·罗氏有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-11655243-B2 | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2023-05-23 | — | — | US | disclosed |
| EP-3814337-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2021-05-05 | — | — | EP | disclosed |
| US-20210115027-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-22 | — | — | US | disclosed |
| CN-112074513-A | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists | 豪夫迈·罗氏有限公司 | 2020-12-11 | — | — | CN | disclosed |
| WO-2020002270-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-01-02 | — | — | WO | disclosed |